These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2037711)

  • 1. Pharmacokinetics of cefprozil in healthy subjects and patients with hepatic impairment.
    Shyu WC; Wilber RB; Pittman KA; Garg DC; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):372-6. PubMed ID: 2037711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
    Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers.
    Shukla UA; Pittman KA; Barbhaiya RH
    J Clin Pharmacol; 1992 Aug; 32(8):725-31. PubMed ID: 1487562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans.
    Shyu WC; Shah VR; Campbell DA; Wilber RB; Pittman KA; Barbhaiya RH
    J Clin Pharmacol; 1992 Sep; 32(9):798-803. PubMed ID: 1430299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excretion of cefprozil into human breast milk.
    Shyu WC; Shah VR; Campbell DA; Venitz J; Jaganathan V; Pittman KA; Wilber RB; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 May; 36(5):938-41. PubMed ID: 1510416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antacid on the bioavailability of cefprozil.
    Shyu WC; Wilber RB; Pittman KA; Barbhaiya RH
    Antimicrob Agents Chemother; 1992 May; 36(5):962-5. PubMed ID: 1510420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of multiple-dose cefprozil and comparison with cefaclor.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1198-203. PubMed ID: 2393281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
    Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
    Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1204-9. PubMed ID: 2393282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefprozil in infants and children.
    Sáez-Llorens X; Shyu WC; Shelton S; Kumiesz H; Nelson J
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2152-5. PubMed ID: 2073105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
    Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute bioavailability of cefprozil after oral administration in beagles.
    Barbhaiya RH; Wang L; Shyu WC; Pittman KA
    Antimicrob Agents Chemother; 1992 Mar; 36(3):687-9. PubMed ID: 1622187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and pharmacokinetics of cefprozil.
    Barriere SL
    Clin Infect Dis; 1992 Jun; 14 Suppl 2():S184-8; discussion S195-6. PubMed ID: 1617036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
    Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple-dose pharmacokinetics of ceftibuten after oral administration to healthy volunteers.
    Bressolle F; Galtier M; Kinowski JM; Goncalves F; Edno L; Panis R; Gomeni R
    J Pharm Sci; 1994 Sep; 83(9):1236-40. PubMed ID: 7830237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of time of administration and posture on the pharmacokinetics of cefprozil.
    Shyu WC; Gleason CR; Barbhaiya RH
    Clin Pharmacokinet; 1993 Sep; 25(3):237-42. PubMed ID: 8222462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.